CN1840707A

CN1840707A - Method for Screening Gene RGS1 of Immune Tolerance Related Diseases Based on Immune Tolerance Dendritic Cells

Info

Publication number: CN1840707A
Application number: CNA2006100130918A
Authority: CN
Inventors: 杨荣存; 刘昱; R.卢登; W.如适; 张园; 张灼寒
Original assignee: Nankai University
Current assignee: Nankai University
Priority date: 2006-01-23
Filing date: 2006-01-23
Publication date: 2006-10-04
Anticipated expiration: 2026-01-23
Also published as: CN1840707B

Abstract

The provided screen method for RGS1 gene on immune tolerance comprises: preparing human immune tolerance dendritic cell by external culture to increase the expression of RGS1 gene in the dendritic cell; when transfecting siRNA of RGS1 gene or aimed genes with monocyte series, affecting activity of transcription factor and expression; and playing special immunoregulation function to guide immune tolerance. This invention has great application potential.

Description

Screen the method for the gene RGS 1 of immunological tolerance associated disease based on the immunological tolerance dendritic cell

Technical field

The present invention relates to the method for the gene RGS 1 of external evoked immunological tolerance dendritic cell screening immunological tolerance associated disease, specifically be immunological tolerance associated disease gene regulator of G protein 1 (hereinafter referred RGS1 gene), screening and authentication method that the new function of known RGS1 is found, RGS1 participate in immunological tolerance and influence the expression of immune response gene.The RGS1 gene is having the potential clinical value aspect the treatment of immune related diseases such as resisting transplant rejection reaction, tumour, inflammation, autoimmune disorder.

Background technology

Famous immunologist Burnet proposed clonal selection theory in 1975, and with clonal deletion (clonal deletion) theory explain immunological tolerance phenomenon.The T, the B reacting cells system that are in mezzanine level are eliminated because of contacting antigen, then cause immunological tolerance.But the understanding to immunological tolerance mechanism surmounts clonal deletion far away at present.It relate to any one positive and negative regulation system in the immunne response process.The clone does not reply may be because immunologically competent cell lacks activation signal; Immunologically competent cell activates and is obstructed; Lack helper and suppress the effect of cell such as the effect that T suppresses cell, other suppress immunocyte such as NKT cell, the restraining effect of scavenger cell.Dendritic cell present cell as the effective antigens of immunity system, play decisive role in immunoreactive startup and immunoreactive regulate process.Dendritic cell can be expressed high-caliber antigen presentation molecule, stimulation molecule, generation broad profile of cytokine and chemokine, and these cells are being controlled innate immunity reaction and response to passive immunization guiding anti-microbial pathogen and anti tumor immune response.

Get immunological tolerance mechanism clear to tumour immunity, graft-rejection and autoimmune disorder have significance.The inducing of immunological tolerance, keep with destroying infection many clinical diseases generation, develop and lapse to.People's attempt is induced and is kept immunotolerance and prevent and treat hypersensitivity disease, autoimmune disorder, the rejection of tumour and graft.In some infectious diseases and the tumor growth process, manage to remove immunological tolerance, excite immunne response will help the removing of pathogenic agent and the control of tumour.In recent years the core of finding immunological tolerance is exactly dendritic cell (Dendritic cell, DC) (Beriouet al., 2005; Coates and Thomson, 2002; Cobbold et al., 2003; Fairchild et al., 2004; MacDonald et al., 2005; Martinez and Rosen, 2005; Quezada et al., 2004; Raimondi and Thomson, 2005; Taner and Thomson, 2004), find like this and identify that the gene that the control dendritic cell participates in inducing immune tolerance will be crucial.Although people find that by other method some can regulate the gene of dendritic cell differentiation and function, this far fails to open the hereditary basis especially relevant with immunological tolerance with function of control dendritic cell differentiation.Up to the present, go back the gene that the none systems approach is identified dendritic cell inner control immunological tolerance.

Regulator of G protein (RGS) is a GTPase activator, and many member compositions are arranged.The member of this family can express at immunocyte such as T cell, B cell and dendritic cell.The GTPase activator function of having identified so far mainly comprises (the Shi GX.5157-5184 that moves that moves (Bowman and Butcher, 28040) and dendritic cell that influences chemokine inductive B cell; Watson.P.623-634).RGS1 knows little as the effect of family member in process of immune regulation of GTPase activator.

Summary of the invention

The objective of the invention is to propose a kind of method of screening the gene RGS 1 of immunological tolerance associated disease based on the immunological tolerance dendritic cell.The expression of RGS1 gene in these immunological tolerance dendritic cell obviously raises.When the siRNA transfection monocytic series of RGS1 gene or these genes of target, the activation of factor, the expression of production of cytokines and costimulatory molecules are transcribed in influence; Importantly can bring into play distinctive immunoloregulation function behind the transfection immunity regulatory cell dendritic cell, the guiding immunological tolerance.These genes are having huge potential using value aspect the treatment of immune related diseases such as resisting transplant rejection reaction, tumour, inflammation, autoimmune disorder.

The present invention is the generation by external evoked immunological tolerance dendritic cell, the immunological tolerance dendritic cell have the morphological structure of immature dendritic cell and the immunostimulation function of reduction has relatively low antigen presentation function, the ability of the guiding immunity specific reaction of reduction.Utilize biochip technology, gene pool bioinformation and modern biology technology screening from immunological tolerance dendritic cell gene RGS 1 relevant with immunological tolerance with evaluation.The function of RGS1 gene has been carried out further evaluation by five different analytical procedures: 1) transfection RGS1 gene pairs is transcribed the influence of factor; 2) influence of signal transducting system related gene expression in transfection RGS1 gene pairs cytokine, chemokine and the cell; 3), transfection RGS1 is to the influence of co stimulatory molecule expression; 4) quiet RGS1 gene pairs tumour related immune tolerance dendritic cell guiding T regulates the influence of cell CD4+CD25+ cell; 5) quiet RGS1 gene pairs dendritic cell opposing tumour is to the influence of dendritic cell; 6), the influence of quiet RGS1 gene pairs dendritic cell antigen presentation function.The immunological tolerance gene of screening is further confirmed by a series of analytical procedures again.

The method based on the gene RGS 1 of immunological tolerance dendritic cell screening immunological tolerance associated disease that the present invention proposes comprises the steps:

(1) preparation of immunological tolerance dendritic cell and evaluation

1) get the medullary cell of healthy C57BL/6 mouse of 4-6 week, remove red corpuscle with water dissolution after, these medullary cells are cultivated at the 1000 GM-CSF (R﹠amp of unit; D company), in the 10%FCSRPMI1640 substratum (ClonTech company), the dendritic cell of 4 days marrow of 37 ℃ of following cultivations origin are as immature dendritic cell.

2) cultivate 4 days immature dendritic cell, give a baby a bath on the third day after its birth time with physiological saline, 24 orifice plates respectively with mouse oophoroma tumor cell, shone ovarian cancer cell or ovarian cancer cell supernatant liquor co-cultivation 9 days.

3) after 9 days, CD80 antibody (BD PharMingen company) with 2 μ l FITC luciferin marks dyes mouse ovarian tumor cell and dendritic cell, then by the mixed cultivation (culture condition: 10%FCSRPMI1640 substratum of flow cytometer from mouse ovarian tumor cell and dendritic cell, 37 ℃) separate dendritic cell, get the immunological tolerance dendritic cell.

4) at first the morphological structure of immunological tolerance dendritic cell is observed, observed the form and the structure of tumour related immune tolerance dendritic cell.

5) after tumour related immune tolerance dendritic cell are given a baby a bath on the third day after its birth time with physiological saline, add anti-CD40, CD80 and the CD86 antibody staining of 2 μ l FITC luciferin marks respectively, flow cytometry analysis is analyzed the expression of immunological tolerance dendritic cell stimulation molecule.

6) with the specific T-cells of class papilloma virus plasmid (VLP) (available from The Johns Hopkins University School ofMedicine) immunized mice guiding as target cell, tumour related immune tolerance dendritic cell with the contrast dendritic cell in load classes papilloma virus plasmid (VLP) back as irritation cell.Co-cultivation 48 hours is got supernatant liquor, by the enzyme-linked immunologic detecting kit IFN-γ content in the clear liquid analytically.

(2) screening of immunological tolerance gene in the immunological tolerance dendritic cell

1) step that at first provides according to Invitrogen company is extracted total RNA from the cancer-related dendritic cell with Trizol reagent (Invitrogen company);

2) the total RNA of cancer-related dendritic cell is analyzed by gene chip, used gene chip is Affymetrix Mouse U74 GeneChip series (U74A, U74B and U74C), analyze by U.S. Univ Johns Hopkins Med (The Johne Hopkins University School of Medicine) genome research chamber:

1, at first, with oligonucleotide and dT as primer (Proligo, Boulder, co) and the synthetic sub-thread cDNA of SuperScript choice (cDNA synthetic agent box SuperScript TM Choice System For cDNA Synthesis Kit).

2, synthetic then bifilar cDNA.Bifilar cDNA utilizes BioArray RNA highyield Transcript labeling test kit (Inzo Bioche) by after phenol-chloroform extracting.Produce Biomylated anti-sensecRNA by in-vitro transcription.

3, with reprocessed cRNA 45 ℃ with Affymetrix genomic gene chip hybridization.Wash with AffymetrixFluidics Station400 and to dye the cRNA that chip is removed not hybridization, use streptavidin-PE then, hatch with goat-anti-streptavidin Ab again in conjunction with BiotimylatedcRNA.With Hewlett-Packard G2500 GeneArray fluorescence intensity.(Affymetrix company) carries out image analysis to each gene chip with MicroArray Suite 5.0 softwares.

4, (Palo Alto, CA), " Lab on a chip " (chip lab) technology confirms that all samples have similar rRNA ratio to adopt Agilent Bioanalyzer.

5, provide bioinformation according to U.S.'s gene pool, provide bioinformation analysis in conjunction with gene pool gene that in the analysis of tumour related immune tolerance dendritic cell gene chip, obviously raises or the gene of obviously reducing.

6, the RGS1 gene is further estimated by sxemiquantitative PCR and quantitative PCR at the high level expression of the relevant dendritic cell of tumour.Provide bioinformation according to gene pool, find out the RGS1 gene order that in tumour related immune tolerance dendritic cell, obviously raises.

Design RGS1 gene primer: 5 ' atgccaggaatgttcttttctgctag-3 ' and 3 ' ctttaaagtatttgcctgaaggtc-5 '.Analyze with the RT-PCR test kit that Invitrogen provides.With SybrGreen I detecting pattern by quantitative PCR, the transcriptional level of the SYBR green I fluorescent dye mensuration RGS1 that provides with TAKARA company.

(3) clone RGS1 gene

At first the step that provides according to Invitrogen company is extracted total RNA from the cancer-related dendritic cell with Trizol reagent.Use the RGS1 primer: 5 ' atgccaggaatgttcttttctgctag-3 ' and 3 ' ctttaaagtatttgcctgaaggtc-5 ', the RT-PCR test kit that provides by Invitrogen company, experimental procedure amplification RGS1 gene according to the said firm provides extracts the RGS1 gene fragment that test kit extracts amplification by Invitrogen glue.The pCDNA that provides by Invitrogen company then _3.1His/V5 ToPo carrier, the experimental procedure that provides according to the said firm arrives pCDNA with the RGS1 gene clone _3.1His/V5 ToPo carrier.At last, determine the RGS1 sequence by checking order.The RGS1 sequence table is:

5’atgccaggaa?tgttcttttc?tgctagccca?aaggattcga?aagaacacag?ccattctctt

ctagacgaca?aaaagcagaa?aaaaaggcca?aagacttttg?gaatggacgt?gaaaacatac

ctgagatcga?tgatcccaca?tctggaatct?gggatgaaat?cggccaagtc?caaagacata

ctttctgctg?aagaagtaat?gcagtggtct?cagtctctgg?aaaaactcct?tgccaaccag

acaggtcaaa?atgtctttgg?aagatttcta?aagtctgaat?tcagtgagga?aaatattgaa

ttctggttgg?cttgtgagga?ctataagaaa?acagagactg?atcttttgca?taacaaagca

gagaatatat?acaaagcatt?tgtgcattca?gatgctgtga?aacaaatcaa?tattgacttc

catactcgag?aatcgacagc?caagaagatt?aaaacaccaa?ctcccacatc?ttttgatgaa

gcacaaaaag?tcatatattc?actcatggaa?aaagattctt?atcccaggtt?cctgaaatca

aatatttact?taaatcttct?aaatgacctt?caggcaaata?ctttaaagtg?a?3’

(4) the tumour related immune tolerance genes involved function of screening is further identified:

1), with being loaded with immunological tolerance gene RGS 1 carrier and pNF-KappaB-Seap reporter gene (CloneTech company) by the common transfection RAW264.7 cell of lipofectin2000 (Invitrogen), stimulate with 1 μ g/mlLPS or 25 μ g/mlPolyI:C then, draw supernatant liquor after 24 hours." Great Esc Ape SEAPChemilumine Scence " detection kit that supernatant liquor provides with clonetech company, the method and the program that provide by clonetech company, the analytically chemiluminescence intensity of clear liquid (Chemilumine Scence).

2), the RAW264.7 of tumour related immune tolerance gene RGS1 transfection, under 600 μ g/ml G418 selection conditions, set up the clone of stable transfection.

The dyeing back is by cell surface stimulation molecule CD40, the CD80 of these stable transfections of flow cytometry analysis and the expression of CD86 and other costimulatory molecules.Simultaneously, analyze the expression of cell 48 hour cell surface C D40, CD80, CD86 and other costimulatory molecules after the stimulation of different Toll-like acceptor connecting keys (1 μ g/ml LPS, 25 μ g/ml Poly I:C 50 μ g/ml PGN and 100nM B.DNA) of these stable transfections.

3), total RNA of the RAW264.7 clone of RGS1 the stable transfection method and the step that provide according to Invitrogen company, extract RNA with Trizol reagent.Total RNA is used for the influence that gene chip is analyzed the expression of signalling system in the RGS1 pair cell factor, chemokine and the cell.

4), quiet RGS1 gene pairs tumour related immune tolerance dendritic cell guiding T regulates the influence of cell CD4+CD25+ cell.Use the siRNA dendritic cell transfection reagent box that AMAXA company provides, the test kit that provides according to the said firm carries out transfection.The ovarian tumor related immune tolerance dendritic cell of the siRNA transfection of target immunological tolerance gene RGS 1 and mouse spleen Native T cell co-cultivation are after 10 days, and flow cytometry analysis CD4+CD25+T regulates the ratio of cell.

RGS1 target sequence 1#:AATGTTCTTTTCTGCTAGCCC;

SiRNA sequence: sense strand siRNA:UGUUCUUUUCUGCUAGCCCtt and antisense strandsiRNA:GGGCUAGCAGAAAAGAACAtt;

RGS1 target sequence 2#:AAAGGATTCGAAAGAACACAG;

SiRNA sequence: sense strand siRNA:AGGAUUCGAAAGAACACAGtt antisense strandsiRNA:CUGUGUUCUUUCGAAUCCUtt.

Contrast siRNA: the artificial mutation form of above-mentioned siRNA (Δ siRNA): siRNA sequence: sense strand siRNA:UGUUCCCUUCUGCUAGUUCtt and antisense strand siRNA:GAACUAGCAGAAGGGAACAtt; AMAXAsiRNA transfection instrument transfection dendritic cell with Germany's production.

5), the influence of quiet RGS1 gene pairs dendritic cell antigen presentation function.

The ovarian tumor related immune tolerance dendritic cell of the siRNA transfection of target immunological tolerance gene RGS 1 stimulate the special t cell responses of class papilloma virus particle behind the load classes papilloma virus plasmid.Concentration by ELISA kit measurement supernatant liquor IFN-γ (interferon-gamma).

6), quiet RGS1 gene pairs dendritic cell opposing tumour is to the influence of dendritic cell.

The Double-Promoter pFIV-H that provides with SBI System Biosciences company ₁/ U ₆SiRNA clone and expression plasmid, the experimental procedure that provides according to the said firm is set up the slow virus infection system of target RGS1 gene.The design of siRNA masterplate and insertion are carried out according to method and step that SBI System Biosciences company provides fully.

RGS1siRNA masterplate 1#:5 ' ctgagatcgatgatcccacatctggaatct-3 and 3 ' gactctagctactagggtgtagaccttaga-5;

RGS1siRNA masterplate 2#:5 ' catactcgagaatcgacagccaag-3 ' and 3 ' gtatgagctcttagctgtcggttc-5 '.Contrast siRNA masterplate:

The mutant form of above-mentioned siRNA masterplate (Δ siRNA): 5 gtcggatcgatgatcccacatctggaatct-3 and 3 ' cagcctagctactagggtgtagaccttaga-5.

Target RGS1 gene siRNA slow-virus transfection dendritic cell are carried in utilization, establish the slow virus contrast of target RGS1 gene siRNA simultaneously.Use the slow-virus transfection dendritic cell, obtain the dendritic cell and the ovarian cancer cell co-cultivation (condition: 10%FCSRPMI1640 substratum of different transfections, 37 ℃), after the week, observe form, structure and antigenic stimulation molecule and the antigen presentation functional analysis of dendritic cell.

The invention provides a very effective method, have great significance in immune related diseases such as resisting transplant rejection reaction, tumour, inflammation, autoimmune disorder research based on immunological tolerance dendritic cell screenings immunological tolerance associated disease gene RGS 1.Set up the method for preparing people's immunological tolerance dendritic cell by vitro culture.Tumour related immune tolerance dendritic cell genetic background is analyzed, screened and identified the immunological tolerance functional gene.RGS1 immunological tolerance gene participates in the guiding of immunological tolerance, in immune related diseases such as resisting transplant rejection reaction, tumour, inflammation, autoimmune disorder the potential using value is arranged.

Positively effect of the present invention specifically describes as follows:

The immunotherapy of RGS1 immunological tolerance gene pairs clinical tumor has the potential using value.Tumour is one of healthy primary disease of harm humans, and past 10 years, people were developed multiple anti-tumor immunotherapy, particularly based on the immunotherapy method of dendritic cell.But up to the present, these methods are far from reaching people's desired result, and an important reasons is exactly the inhibition of tumour to stem cell and dendritic cell differentiation and function.Tumour cell can be by directly contact, the tolerance of factors such as the release of cytokine guiding dendritic cell.The discovery and the evaluation of immunological tolerance gene in the dendritic cell can reduce immunological tolerance expression of gene in the dendritic cell by biology techniques such as siRNA silence or fragment deletions, and the opposing tumour cell is to the restraining effect of dendritic cell.This can become a kind of new tool of immunotherapy of tumors.

RGS1 immunological tolerance gene pairs graft-rejection clinical treatment has the potential using value.Histoorgan is transplanted has become one of medically important treatment means.Carried out liver of the same race, kidney, spleen, pancreas islet, small intestine transplantation clinically, and liver kidney, liver pancreas, cardiopulmonary, etc. combined transplantation.Because graft is taken from another different individuality of genetic background usually, often occurs rejection after the transplanting.Setting up the receptor is to transplant the target that the scholar pursues to the antigenic immunological tolerance of graft tissue.Dendritic cell are being controlled immune response, and the dendritic cell of immunological tolerance gene RGS 1 gene transfection have the function of guiding immunological tolerance, can treat graft-rejection by the dendritic cell that the RGS1 transfection is modified.

RGS1 immunological tolerance gene pairs autoimmune disorder, the clinical treatment of hypersensitivity disease and infectious diseases has the potential using value.Dendritic cell are most important antigen presenting cells, and these cells not only can guide immune response, also can guide immunological tolerance, and the dendritic cell of the siRNA transfection of RGS1 transfection or these genes of target can become a kind of new tool of these disease treatments.

In addition, discovery such as nano material along with modern biomaterial, these gene siRNAs of RGS1 immunological tolerance gene and target can directly be targeted to dendritic cell, performance immunoloregulation function, treatment and immune diseases associated such as autoimmune disorder, anti-rejection, tumour etc.

Description of drawings

Fig. 1, tumour related immune tolerance dendritic cell do not possess the feature of mature dendritic cell.

Fig. 2, RGS1 are at tumour related immune tolerance dendritic cell high level expression.

Fig. 3, tumour related immune tolerance gene RGS1 1 suppress the activation of immuno-stimulating factor to the factor of transcribing.

Fig. 4, tumour related immune tolerance gene RGS1 1 suppress the expression of stimulation molecule CD40.

Fig. 5, quiet RGS1 have reduced the relevant dendritic cell guiding of tumour T and have regulated the ability that the CD4+CD25+ cell produces.

Fig. 6, quiet RGS1 have promoted the relevant dendron cell antigen of tumour to present function.

Fig. 7, the slow-virus transfection that carries target RGS1 gene siRNA have promoted the restraining effect of dendritic cell opposing tumour cell.

Fig. 8, the slow-virus transfection that carries target RGS1 gene siRNA have promoted tumour related immune tolerance dendritic cell antigen presentation function.

Embodiment

Below by embodiment the present invention is specifically described; be necessary to be pointed out that at this present embodiment only is used for the present invention is further detailed; can not be interpreted as limiting the scope of the invention, the person skilled in the art of this area can make some nonessential improvement and adjustment according to the content of the invention described above.

Embodiment 1:

The preparation of immunological tolerance dendritic cell.

Concrete preparation method:

1.1. experiment material:

1), substratum is the PRMI1640 substratum (Hyclone company) that contains 10% calf serum (people's marine life company), adds 1% penicillin and 1% Streptomycin sulphate (Sigma company) simultaneously.37 ℃ of experimental temperature conditions.Below the substratum in the record all is this substratum.

2), ovarian tumor cell is the tumour cell from mouse ovarian tumor separate tissue; Ovarian tumor cell is provided by Dr.KatherineRoby (Carcinogenesis, 21:585-591,2000).In order to determine inducing by cell of dendritic cell of tumour related immune tolerance to contact or the excretory factor of tumour cell own with the direct of cell, we have carried out following processing to ovarian cancer cell:

A, with 14000 Rad Co ₆₀The irradiation ovarian cancer cell.This class cell is used to estimate the direct influence that contacts of cell and cell.

The culture supernatant of B, ovarian cancer cell.Cultivate 4 days supernatant liquors of ovarian cancer cell and be used to regulate the influence of emiocytosis factor.

C, undressed ovarian cancer cell are used to estimate the influence of the secretory product of the direct effect of cell and cell and cell to dendritic cell.

3), dendritic cell are at the GM-CSF factor (R﹠amp by medullary cell; D company) under the effect, guiding produces.4-6 week healthy C57BL/6 (available from Military Medical Science Institute of PLA) mouse, after disconnected neck is put to death, extracting marrow cell, behind sterilized distilled water dissolving removal red corpuscle, these medullary cells are cultivated at 1000 GM-CSF of unit, in the 10%FCSRPMI1640 substratum.The dendritic cell that the marrow of cultivating 4 days originates from are as immature dendritic cell.

1.2. the guiding of immunological tolerance dendritic cell.

A. cultivate 4 days immature dendritic cell, give a baby a bath on the third day after its birth time with physiological saline, 24 orifice plates respectively with mouse oophoroma tumor cell, shone ovarian cancer cell or ovarian cancer cell supernatant liquor co-cultivation 9 days.The ratio of ovarian tumor cell and dendritic cell is 1: 10.The ratio of ovarian cancer cell supernatant liquor and fresh culture is 1: 3.

B.9 the dendritic cell of day these processing of back separate with ovarian cancer cell by flow cytometer.CD80 antibody (PharMingen) with 2 μ l FITC luciferin marks dyes ovarian tumor cell and dendritic cell, then by the mixed culture of isolated dendritic cell of flow cytometer (B.D.FAScanBUR) from ovarian tumor cell and dendritic cell.In this co-cultivation system, after 9 days, tumour cell is most to disappear automatically, does not need a nearly step flow cytometer to separate.The dendritic cell contrast.Not with the dendritic cell of tumour cell co-cultivation cell in contrast, in order to guarantee to contrast the comparability of dendritic cell, with also separating to get rid of the cell of other pollutions behind the CD80 antibody staining of 2 μ l FITC luciferin marks by flow cytometer.

1.3, the evaluation of immunological tolerance dendritic cell.

A. at first the morphological structure of immunological tolerance dendritic cell is observed, tumour related immune tolerance dendritic cell do not possess the feature of mature dendritic cell.Fig. 1, tumour related immune tolerance dendritic cell do not possess the feature of mature dendritic cell.

B. the immunological tolerance dendritic cell are expressed low-level stimulation molecule.In order to determine the expression of tumour related immune tolerance dendritic cell costimulatory molecules CD40, CD80 and CD86, after tumour related immune tolerance dendritic cell are given a baby a bath on the third day after its birth time with physiological saline, anti-CD40, the CD80 and the CD86 antibody that add 2 μ l FITC luciferin marks respectively, flow cytometry analysis.Figure 1B has shown the expression (a: antibody subtype contrast of the costimulatory molecules that tumour related immune tolerance dendritic cell reduce; B: control group dendritic cell; C: tumour related immune tolerance dendritic cell).

C. the immunological tolerance dendritic cell have the ability of the guiding immunity specific reaction of relatively low antigen presentation function and reduction.

For the antigen worker who observes the relevant immunological tolerance dendritic cell of tumour present function _ (J.Virology, 2004,11152-11160), the specific T-cells that guides with class papilloma virus plasmid (VLP) immunized mice is used as target cell (2 * 10 ⁶), tumour related immune tolerance dendritic cell are back as irritation cell at load classes papilloma virus plasmid (VLP) with the contrast dendritic cell.Co-cultivation 48 hours is got supernatant, by elisa kit (R﹠amp; D Co.) the IFN-γ content in the clear liquid analytically.The result has shown that the immunological tolerance dendritic cell have the ability (Fig. 1 C) of the guiding immunity specific reaction of relatively low antigen presentation function and reduction.

Fig. 1, tumour related immune tolerance dendritic cell do not possess the feature of mature dendritic cell.Tumour related immune tolerance dendritic cell under A, the light microscopic, A1: control group dendritic cell; A2: tumour related immune tolerance dendritic cell.The expression of B, tumour related immune tolerance dendritic cell costimulatory molecules, a: antibody subtype contrast; B: control group dendritic cell; C: tumour related immune tolerance dendritic cell.The antigen presentation ability that C, tumour related immune tolerance dendritic cell reduce, DC: contrast dendritic cell; The immunological tolerance dendritic cell that the T.DC tumour is relevant; Contr.: dendritic cell only.DC:T: the ratio of dendritic cell and T cell.

2. the evaluation of immunological tolerance gene in the immunological tolerance dendritic cell.

The present invention is in order to determine or identify the immunological tolerance gene that tumour is relevant that total RNA analyzes by gene chip to the cancer-related dendritic cell.At first the step that provides according to Invitrogen company is extracted total RNA from the cancer-related dendritic cell with Trizol reagent.

2.1. gene chip analytical procedure:

A, the total RNA of 5 μ g are used for synthetic sub-thread cDNA.With oligonucleotide and dT as primer (Proligo, Boulder, co) and the synthetic sub-thread cDNA of SuperScript choice, synthetic then bifilar cDNA.

B, bifilar cDNA utilize BioArray RNA high yield Transcript labeling test kit (Inzo Bioche) by after phenol-chloroform extracting.Produce Biomylated anti-sense cRNA by in-vitro transcription.The BiotimylatedcRNA of 15mg handles 35 minutes (100mM Trix-acetate at 94 ℃, PH8.2,500mM KoAc, 150mM MgOAc), the cRNA of the total processing of 10ug subsequently 45 ℃ with Affymetrix people's gene group gene chip hybridization, shook (60rpm) gently 16 hours.Wash with Affymetrix Fluidics Station400 and to dye the cRNA that chip is removed not hybridization, use streptavidin-PE then, hatch (25 ℃) with goat-anti-streptavidin Ab again in conjunction with Biotimylated cRNA.With Hewlett-Packard G2500 GeneArray fluorescence intensity.With MicroArray Suite 5.0 softwares (Affymetrix) each gene chip is carried out image analysis.For more different chips, use global yardstick, determine 150 as fluorescence intensity level.

C, in order to ensure comparability from different samples, adopt Agilent Bioanaiyzer (Palo Alto, CA), " Labon a chip " technology has confirmed that all samples have similar rRNA ratio, 188 and the 28S ratio be 1: 2 and " Run pattern " (electrophoretic band) clearly.Same, also be used to confirm cRNA and the cRNA of fragmentation (fragmentedcRNA).In order to ensure the quality of hybridization, the Genechip image, the comparison between the different chips, we have also studied following parameter: class parameter (scaling factor); Background; Keep gene.For quality of evaluation control, we have also compared the per-cent of the different rises of each group with downward modulation.Initial expression of results is based on the comparison under the different experimental conditions, and the expression level of test group and control group shows 2 times variation at least, just is considered to meaningful.

2.2. by mouse tumour related immune tolerance dendritic cell are compared with the contrast dendritic cell, show that as Fig. 2 a part of gene is raised, and another part gene is reduced.In the relevant immunological tolerance gene of these ovarian tumors (gene that ovarian tumor raises or reduces), RGS1 obviously raises (Fig. 2 A).Obviously the RGS1 gene that raises is further confirmed by sxemiquantitative PCR (Fig. 2 B) and quantitative PCR (Fig. 2 C) at the high level expression of the relevant dendritic cell of ovarian tumor.RGS1 primer: 5 ' atgccaggaatgttcttttctgctag-3 ' and 3 ' ctttaaagtatttgcctgaaggtc-5 '.

Fig. 2, RGS1 are at tumour related immune tolerance dendritic cell high level expression.A, tumour related immune tolerance dendritic cell gene chip are analyzed.T.DC: the tumour dendritic cell of being correlated with; DC: contrast dendritic cell.B1 and C1:RGS1 are in the expression of contrast dendritic cell; B2 and the expression of C2:RGS1 at the relevant dendritic cell of tumour.B, sxemiquantitative PCR, C, quantitative PCR; R.E: relative intensity; GAPDH: the positive genetic contrast that keeps.

3, the clone of the relevant tolerance gene of RGS1 immunity.

At first the step that provides according to Invitrogen company is extracted total RNA from the cancer-related dendritic cell with Trizol reagent.Use the RGS1 primer: 5 ' atgccaggaatgttcttttctgctag-3 ' and 3 ' ctttaaagtatttgcctgaaggtc-5 ', the RT-PCR test kit that provides by Invitrogen company, experimental procedure amplification RGS1 gene according to the said firm provides extracts the RGS1 gene fragment that test kit extracts amplification by Invitrogen glue.The pCDNA that provides by Invitrogen company then _3.1His/V5 ToPo carrier, the experimental procedure that provides according to the said firm arrives pCDNA with the RGS1 gene clone _3.1His/V5 ToPo carrier.At last, determine the RGS1 sequence by checking order:

5’atgccaggaa?tgttcttttc?tgctagccca?aaggattcga?aagaacacag?ccattctctt

ctagacgaca?aaaagcagaa?aaaaaggcca?aagacttttg?gaatggacgt?gaaaacatac

ctgagatcga?tgatcccaca?tctggaatct?gggatgaaat?cggccaagtc?caaagacata

ctttctgctg?aagaagtaat?gcagtggtct?cagtctctgg?aaaaactcct?tgccaaccag

acaggtcaaa?atgtctttgg?aagatttcta?aagtctgaat?tcagtgagga?aaatattgaa

ttctggttgg?cttgtgagga?ctataagaaa?acagagactg?atcttttgca?taacaaagca

gagaatatat?acaaagcatt?tgtgcattca?gatgctgtga?aacaaatcaa?tattgacttc

catactcgag?aatcgacagc?caagaagatt?aaaacaccaa?ctcccacatc?ttttgatgaa

gcacaaaaag?tcatatattc?actcatggaa?aaagattctt?atcccaggtt?cctgaaatca

aatatttact?taaatcttct?aaatgacctt?caggcaaata?ctttaaagtg?a?3’

3, determining screening tumour related immune tolerance gene function.

4.1, tumour related immune tolerance gene RGS1 is to the influence of the factor of transcribing.

In order to determine the influence of RGS1 gene pairs immunoloregulation function.Pass through the common transfection RAW264.7 cell of lipofectin2000 (Invitrogen) with carrier that is loaded with the immunological tolerance gene RGS 1 and pNF-KappaB-Seap reporter gene (CloneTech company), stimulate with 1 μ g/mlLPS or 25 μ g/ml PolyI:C then, draw supernatant after 24 hours." Great Esc Ape SEAP Chemilumine Scence " detection kit that supernatant liquor provides with clonetech company, the method and the program that provide by clonetech company, the analytically chemiluminescence intensity of clear liquid (Chemilumine Scence).Just as shown in Figure 3, RGS1 has obviously suppressed LPS and PolyI:C to transcribing the activation of factor NF-kappaB.

Fig. 3, tumour related immune tolerance gene RGS1 1 suppress the activation of immuno-stimulating factor to the factor of transcribing.RAW264.7: mononuclear phagocyte system contrast; The mononuclear phagocyte of TRAW264.7:RGS1 transfection.Contr: only RAW264.7 or TRAW264.7 supernatant liquor; LPS: stimulate RAW264.7 or TRAW264.7 supernatant liquor with 1 μ g/ml LPS; Poly I:C: stimulate RAW264.7 or TRAW264.7 supernatant liquor with 25 μ g/ml Poly I:C.Chemiluminescence intensity is detected by the test kit that cloning companies provides.

4.2, tumour related immune tolerance gene RGS1 influence that costimulatory molecules is expressed.

The RAW264.7 of tumour related immune tolerance gene RGS1 transfection under 600 μ g/ml G418 selection conditions, sets up the clone of stable transfection.The dyeing back is by cell surface stimulation molecule CD40, the CD80 of these stable transfections of flow cytometry analysis and the expression of CD86 and other costimulatory molecules.Simultaneously, the cell of analyzing these stable transfections was back 48 hours of the stimulation of different Toll-like acceptor connecting key (1 μ g/ml LPS, 25 μ g/ml Poly I:C 50 μ g/ml PGN and 100nM B.DNA).The expression of cell surface CD40, CD80, CD86 and other costimulatory molecules.As shown in Figure 4.The RGS1 transfection has obviously reduced RAW264.7 to the response capacity that Toll-like acceptor connecting key stimulates, and has reduced the expression of CD40.Fig. 4, tumour related immune tolerance gene RGS1 1 suppress the expression of stimulation molecule CD40.A: antibody subtype contrast; B: the mononuclear phagocyte of tumour related immune tolerance gene transfection; C: the mononuclear phagocyte contrast of untransfected.The Raw264.7 of RGS1 gene transfection and untransfected is giving 100nM B.DNA, 1 μ g/ml LPS, and 25 μ g/ml PGN, 25 μ g/ml Poly I:C stimulated after 48 hours, the expression of CD40.

4.3, the influence of signalling system developed by molecule in the tumour related immune tolerance gene RGS1 pair cell factor, chemical chemotactic chair, cell.Method and step that total RNA of the RAW264.7 clone of RGS1 stable transfection provides according to invitrogen company are extracted with Trizol reagent.Total RNA is used for the gene chip analysis.Compare with the RAW264.7 cell of contrast untransfected, RGS1 has obviously influenced the expression (table 1-3) of signalling system in some cytokines, chemokine and the cell.

The influence of table 1, the tumour related immune tolerance gene RGS1 pair cell factor and related gene expression.

Gene?Title Gene?Symbol control RGS1

interleukin?2?receptor，gamma?chain ll2rg 305.8 470.8

interleukin?18 ll18 645.5 457.3

interleukin?enhancer?binding?factcr?2 ll12 50.4 2.4

interleukin?15 ll15 50.1 209.7

interleukin?1?family，member?6 ll116 371.4 327.6

interleukin?17?receptor ll17r 333.1 224.6

interleukin?17?receptor ll17r 547.5 438.1

interleukin?6?signaltransducer ll6st 107.2 100.1

interleukin?1?alpha ll1a 2398.2 1872.4

interleukin-1?receptor-associated?kinase?4 lrak4 140.3 76.2

interleukin?15?receptor，alpha?chain ll15ra 175.2 376.1

interleukin?1?receptor?antagonist ll1rn 3006.9 1976.5

interleukin?1?family，member?9 ll119 563.6 570.8

interleukin?13?receptor，alpha?1 ll13ra1 67.6 79.2

interleukin-1?receptor-associated?kinase?3 lrak3 670.6 290.1

interleukin-1?receptor-associated?kinase?3 lrak3 1001.6 551.6

interleukin?15?receptor，alpha?chain ll15ra 118.8 496.4

interleukin?1?bete ll1b 7108.3 6342.5

interleukin?6 ll6 872.3 2909.1

interleukin?10 ll10 220.1 52.6

interleukin?18?binding?protein ll18bp 64.8 12.1

interleukin?1?receptor-like?1?ligand ll1rl1l 256.7 283.4

interleukin?13?receptor，alpha?1 ll13ra1 234.3 190.3

Table 2, tumour related immune suppressor gene RGS1 are to the influence of chemokine and related gene expression thereof.

Gene?Title Gene?Symbol Contr RGS1

chemokine(C-C?motif)ligand?6 Ccl6 307?1 265?5

chemokine(C-X-C?motif)ligand?7 Cxcl7 28?1 6?9

chemokine(C-X-C?motif)ligand?10 Cxcl10 4153 6534?7

chemokine(C-C?motif)ligand?12 Ccl12 2065?8 442?9

chemokine(C-X-C?motif)ligand?11 Cxcl11 135?6 292?6

chemokine(C-C?motif)ligand?6 Ccl6 114?8 70?3

chemokine(C-C?motif)ligand?2 Ccl2 26506?3 21279?9

chemokine(C-C?motif)ligand?7 Ccl7 5897?4 5157?9

chemokine(C-C?motif)ligand?4 Ccl4 21904?6 19454?3

chemokine(C-X-C?motif)receptor?4 Cxcr4 87?7 166?9

chemokine(C-X-C?motif)ligand?4 Cxcl4 2757?2 1430?7

chemokine(C-X-C?motif)ligand?2 Cxcl2 10286?6 10836

chemokine(C-C?motif)ligand?24 Ccl24 11?2 20?1

chemokine(C-X-C?motif)ligand?1 Cxcl1 160 255

The influence that the signalling system associated molecule is expressed in table 3, the tumour related immune suppressor gene RGS1 pair cell.

Gene?Title Gene?Symbol Conyr RGS1

Rho?GTP?ase?activating?protein?9 Arhgap9 527.3 552?1

Rho?GTP?ase?activating?protein?1 Arhgap1 430.6 311?1

Rho?GTP?ase?activating?protein?24 Arhgap24 149.6 293?2

Rho?GTP?ase?activating?protein?10 Arhgap10 228.8 245?8

Rho?GTP?ase?activating?protein?17 Arhgap17 358 234.3

activating?transcription?factor?2 Atf2 214 306.7

Rho?GTP?ase?activating?protein?18 Arhgap18 69.2 27.6

IQ?motif?containing?GTP?ase?activating?protein?1 Iqgap1 119?7 86.6

Rho?GTP?ase?activating?protein?9 Arhgap9 631.7 463.2

activating?transcription?factor?7 Atf7 60.4 135?1

Rho?GTP?ase?activating?protein?11A Arhgap11a 268?7 123.1

activating?transcription?factor?4 Atf4 8303 9105.9

activating?transcription?factor?3 Atf3 3868.3 6975.6

Rho?GTP?ase?activating?protein?9 Arhgap9 256.3 222?8

apoptotic?protease?activating?facter?1 Apaf1 119.6 115.6

Rac?GTP?ase-activating?protein?1 Racgap1 819?5 383.6

Rho?GTP?ase?activating?protein?12 Arhgap12 158.3 134

cyclin-dependent?kmase?7 Cdk7 126.6 171?9

activating?transcnption?factor?2 Atf2 217?1 166?3

apoptotic?protease?activating?factor?1 Apaf1 205.4 165.6

Cdc42?GTP?ase-activating?protein Cdgap 179 92.7

T-cell?activation?GTP?ase?activating?protein?1 Tagap1 373.5 279.9

Table 1-3: the gene chip analysis of the Raw264.7 of transfection RGS1 gene: Contr: the Raw264.7 cell of untransfected RGS1 gene.RGS1: the Raw264.7 cell of transfection RGS1 gene.

4.4, the siRNA of quiet tumour related immune tolerance gene RGS1 suppresses the generation that tumour related immune tolerance cell guiding CD4+CD25+T regulates cell.Use the siRNA dendritic cell transfection reagent box that AMAXA company provides, the test kit that provides according to the said firm carries out transfection.The ovarian tumor related immune tolerance dendritic cell of the siRNA transfection of target immunological tolerance gene RGS 1 and mouse spleen Native T cell co-cultivation are after 10 days, flow cytometry analysis CD4+CD25+T regulates the ratio of cell, the result has shown the expression of the quiet dendritic cell immune suppressor genes of immunological tolerance gene siRNA, has obviously suppressed the generation (Fig. 5) of CD4+CD25+T adjusting cell.

RGS1 target sequence 1#:AATGTTCTTTTCTGCTAGCCC;

SiRNA sequence: sense strand siRNA:UGUUCUUUUCUGCUAGCCCtt and antisense strand siRNA:GGGCUAGCAGAAAAGAACAtt;

RGS1 target sequence 2#:AAAGGATTCGAAAGAACACAG;

Contrast siRNA: the artificial mutation form of above-mentioned siRNA (Δ siRNA): sense strand siRNA:UGUUCCCUUCUGCUAGUUCtt and antisense strand siRNA:GAACUAGCAGAAGGGAACAtt;

Nucleofector nucleic acid transfection instrument (AMAXA company) transfection dendritic cell with Germany's production.Evaluation is to the influence of dendritic cell.

Fig. 5, quiet RGS1 have reduced the relevant dendritic cell guiding of tumour T and have regulated the ability that the CD4+CD25+ cell produces.T.siRNADC: the tumour of the target RGS1 gene siRNA transfection dendritic cell of being correlated with; T.MsiRNA: the relevant dendritic cell of tumour of contrast siRNA transfection.

4.5, quiet RGS1 promoted the relevant dendron cell antigen of tumour to present function.The ovarian tumor related immune tolerance dendritic cell load classes papilloma virus plasmid of the siRNA transfection of target immunological tolerance gene RGS 1 can stimulate the special t cell responses of class papilloma virus particle, the generation of guiding IFN-γ.As shown in Figure 6, IFN-γ level is apparently higher than the dendritic cell of contrast siRNA (Δ siRNA) infection.Fig. 6, quiet RGS1 have promoted the relevant dendron cell antigen of tumour to present function.

4.6, carry the restraining effect that target RGS1 gene siRNA slow-virus transfection has promoted dendritic cell opposing tumour cell.For the further influence of decision RGS1 immunological tolerance gene pairs dendritic cell function, set up the slow virus infection system of carrying target RGS1 gene siRNA.The Double-PromoterpFIV-H that SBI System Biosciences company provides ₁/ U ₆SiRNA clones and has expressed plasmid.The design of siRNA masterplate and insertion are carried out according to method and step that SBI SystemBiosciences company provides fully.RGS1siRNA masterplate 1#:5 ' ctgagatcgatgatcccacatctggaatct-3 and 3 ' gactctagctactagggtgtagaccttaga-5; RGS1siRNA masterplate 2#:5 ' catactcgagaatcgacagccaag-3 ' and 3 ' gtatgagctcttagctgtcggttc-5 ' contrast siRNA masterplate: the mutant form of above-mentioned siRNA (Δ siRNA:5gtcggatcgatgatcccacatctggaatct-3 and 3 ' cagcctagctactagggtgtagaccttaga-5..Transfection efficiency can be by the detection of expression of self GFP.Target RGS1 gene siRNA slow-virus transfection dendritic cell are carried in utilization, establish the slow virus contrast of target RGS1 gene siRNA simultaneously.Use the slow-virus transfection dendritic cell, as Fig. 7,90% dendritic cell transfection.Obtain the dendritic cell and the ovarian cancer cell co-cultivation of different transfections, after the week, observed form, structure and the antigenic stimulation molecule of dendritic cell.The result has clearly showed, carry the slow virus of target tumor immunological tolerance gene siRNA, obviously the opposing ovarian cancer cell is to the influence of dendritic cell, carry the slow virus of contrast siRNA and then can not resist the inhibition effect of oophoroma tumor cell, cause the generation (Fig. 7) of tolerance dendritic cell dendritic cell.

The slow-virus transfection that Fig. 7 carries target RGS1 gene siRNA has promoted the restraining effect that dendritic cell are resisted tumour cell.A: the slow-virus transfection dendritic cell of integrating target tumor related immune tolerance gene RGS1SiRNA.Dendritic cell under A1, the light microscopic; A2, GFP are in the expression of the dendritic cell of slow-virus transfection.Δ siRNA: the dendritic cell of contrast siRNA slow-virus transfection; The dendritic cell of siRNA:RGS1 siRNA slow-virus transfection.

4.7, target immunological tolerance gene siRNA promoted the antigen presentation function of dendritic cell.

The dendritic cell of target RGS1 gene siRNA slow-virus transfection have stronger antigen presentation function, the t cell responses that the dendritic cell of the different siRNA slow-virus transfections of load classes papilloma virus plasmid can stimulate class papilloma virus particle to stimulate.As shown in Figure 8, IFN-γ level is apparently higher than the dendritic cell that carry contrast siRNA slow virus infection.Fig. 8, the slow-virus transfection that carries target RGS1 gene siRNA have promoted the restraining effect of dendritic cell opposing tumour cell.DC: control group dendritic cell; T.DC: tumour related immune tolerance dendritic cell; T.siRNADC: the tumour of the target RGS1 gene siRNA slow-virus transfection dendritic cell of being correlated with; T. Δ siRNA: the relevant dendritic cell of tumour of contrast siRNA slow-virus transfection; Dendritic cell only: only contrast dendritic cell and transfection dendritic cell.DC:T: the ratio of dendritic cell and T cell.

4.8, the tumour immunity tolerance gene suppresses the dendritic cell maturation of immunostimulation factor guiding.Immunostimulation factor such as Toll-like acceptor connecting key (LPS, Poly I:C, CPG and PGN) can activate the NF-KappaB signal pathway, the maturation of guiding dendritic cell.Tumour immunity tolerance gene RGS1, the monocyte RAW264.7 of transfection can resist these Toll-like acceptor connecting keys to transcribing the activation of factor NF-KappaB, stop the expression (Fig. 3, Fig. 4) of costimulatory molecules.

Sequence table

SEQUENCE?LISTING

＜110〉Nankai University

＜120〉based on the method for the gene RGS 1 of immunological tolerance dendritic cell screenings immunological tolerance associated disease

<130>2006021

<160>1

<170>PatentIn?version?3.3

<210>1

<211>591

<212>DNA

＜213〉mouse mouse

<400>1

atgccaggaa?tgttcttttc?tgctagccca?aaggattcga?aagaacacag?ccattctctt 60

ctagacgaca?aaaagcagaa?aaaaaggcca?aagacttttg?gaatggacgt?gaaaacatac 120

ctgagatcga?tgatcccaca?tctggaatct?gggatgaaat?cggccaagtc?caaagacata 180

ctttctgctg?aagaagtaat?gcagtggtct?cagtctctgg?aaaaactcct?tgccaaccag 240

acaggtcaaa?atgtctttgg?aagatttcta?aagtctgaat?tcagtgagga?aaatattgaa 300

ttctggttgg?cttgtgagga?ctataagaaa?acagagactg?atcttttgca?taacaaagca 360

gagaatatat?acaaagcatt?tgtgcattca?gatgctgtga?aacaaatcaa?tattgacttc 420

catactcgag?aatcgacagc?caagaagatt?aaaacaccaa?ctcccacatc?ttttgatgaa 480

gcacaaaaag?tcatatattc?actcatggaa?aaagattctt?atcccaggtt?cctgaaatca 540

aatatttact?taaatcttct?aaatgacctt?caggcaaata?ctttaaagtg?a 591

Claims

1. A method for screening the gene RGS1 of immune tolerance-related diseases based on immune tolerance dendritic cells, characterized in that it comprises the following steps:

(1) Preparation and identification of immune tolerance dendritic cells

1) Take bone marrow cells from 4-6-week-old mice, dissolve them with water to remove red blood cells, culture them in 1000 units of GM-CSF, 10% FCSRPMI1640 medium, and culture them at 37°C for 4 days as immature dendritic cells derived from bone marrow of dendritic cells;

2) The immature dendritic cells were washed three times with normal saline, and co-cultured with mouse ovarian cancer cells, irradiated ovarian cancer cells or supernatants of ovarian cancer cells for 9 days;

3) Stain mouse ovarian tumor cells and dendritic cells with 2 μl FITC-fluorescein-labeled CD80 antibody, mix and culture mouse ovarian tumor cells and dendritic cells in 10% FCSRPMI1640 medium, culture at 37°C for 9 days, and use flow cytometry Isolate dendritic cells by using an instrument to obtain immune tolerance dendritic cells;

4) Firstly, the morphology and structure of immune tolerance dendritic cells were observed, and the morphology and structure of tumor-associated immune tolerance dendritic cells were observed;

5) After the tumor-associated immune tolerance dendritic cells were washed three times with normal saline, 2 μl of FITC fluorescein-labeled anti-CD40, CD80 and CD86 antibodies were added for staining, and analyzed by flow cytometry to analyze immune tolerance dendritic cell stimulating molecules expression;

6) Specific T cells guided by papillomavirus-like plasmid (VLP) immunized mice were used as target cells, tumor-associated immune tolerance dendritic cells and control dendritic cells were loaded with papillomavirus-like plasmid (VLP) as stimulator cells ; Co-cultivate for 48 hours, take the supernatant, and analyze the IFN-γ content in the supernatant by an enzyme-linked immunoassay kit;

(2) Screening of immune tolerance genes in immune tolerance dendritic cells

1) Total RNA was extracted from tumor-associated dendritic cells with Trizol reagent;

2) The total RNA of tumor-associated dendritic cells was analyzed by gene chip. The gene chip used was Affymetrix Mouse U74 GeneChip series (U74A, U74B and U74C), which was analyzed by Genome Research Laboratory of Johns Hopkins University School of Medicine in the United States:

1. Use oligonucleotides and dT as primers and SuperScript choice to synthesize single-stranded cDNA;

2. Then double-stranded cDNA was synthesized. After the double-stranded cDNA was extracted with phenol-chloroform (1:1 volume), BioArray RNA high yield Transcript labeling kit was used to produce Biomylated anti-sense cRNA through in vitro transcription;

3. The treated cRNA was hybridized with the Affymetrix genome gene chip at 45°C, and the gene chip was washed and stained with Affymetrix Fluidics Station400 to remove unhybridized cRNA, and then biotimylated cRNA was combined with streptavidin-PE, and then incubated with goat anti-streptavidin Ab; Hewlett-Packard G2500 GeneArray was used to detect the fluorescence intensity, and MicroArray Suite 5.0 software was used to analyze the image of each gene chip;

4. Use Agilent Bioanalyzer (Palo Alto, CA) and "Lab on a chip" (chip laboratory) to confirm that all samples have similar rRNA ratios,

5. Based on the biological information provided by the American gene bank, analyze the genes that are significantly up-regulated or significantly down-regulated in the gene chip analysis of tumor-related immune tolerance dendritic cells combined with the biological information provided by the gene bank;

6. The high-level expression of RGS1 gene in tumor-associated dendritic cells is further evaluated by semi-quantitative PCR and quantitative PCR, and the biological information provided by the gene bank is used to find out the RGS1 gene sequence that is significantly up-regulated in tumor-associated immune tolerance dendritic cells ;sequence:

5’atgccaggaa tgttcttttc tgctagccca aaggattcga aagaacacag ccattctctt

ctagacgaca aaaagcagaa aaaaaggcca aagacttttg gaatggacgt gaaaacatac

ctgagatcga tgatcccaca tctggaatct gggatgaaat cggccaagtc caaagacata

ctttctgctg aagaagtaat gcagtggtct cagtctctgg aaaaactcct tgccaaccag

acaggtcaaa atgtctttgg aagatttcta aagtctgaat tcagtgagga aaatattgaa

ttctggttgg cttgtgagga ctataagaaa acagagactg atcttttgca taacaaagca

gagaatatat acaaagcatt tgtgcattca gatgctgtga aacaaatcaa tattgacttc

catactcgag aatcgacagc caagaagatt aaaacaccaa ctcccacatc ttttgatgaa

gcacaaaaag tcatatattc actcatggaa aaagattctt atcccaggtt cctgaaatca

aatatttact taaatcttct aaatgacctt caggcaaata ctttaaagtg a 3’

Design RGS1 gene primers: 5'atgccaggaatgttcttttctgctag-3' and 3'ctttaaagtatttgcctgaaggtc-5', use the RT-PCR kit provided by Invitrogen for analysis, use SybrGreen I detection mode to pass quantitative PCR, and use SYBR green I fluorescence provided by TAKARA company The dye measures the transcription level of RGS1;

(3) Clone the RGS1 gene

Extract total RNA from tumor-associated dendritic cells with Trizol reagent, use RGS1 primers: 5'atgccaggaatgttcttttctgctag-3' and 3'ctttaaagtatttgcctgaaggtc-5', use the RT-PCR kit provided by Invitrogen, and follow the experimental steps provided by the company Amplify the RGS1 gene, extract the amplified RGS1 gene fragment through the Invitrogen gel extraction kit, and then clone the RGS1 gene into pCDNA _3.1 His/V5 through the pCDNA _3.1 His/V5 ToPo vector provided by Invitrogen according to the experimental procedures provided by the company ToPo vectors, and finally, the sequence of RGS1 listed above was confirmed by sequencing;

(4) Further identification of the functions of the screened tumor-associated immune tolerance-related genes:

1) RAW264.7 cells were co-transfected with the RGS1 vector carrying the immune tolerance gene and the pNF-KappaB-Seap reporter gene through lipofectin2000 (Invitrogen), then stimulated with 1 μg/ml LPS or 25 μg/ml PolyI:C, and pipetted after 24 hours Supernatant, for the supernatant, the Great Esc Ape SEAPCherniluminum Scence Detection Kit was used to analyze the chemiluminescent intensity of the supernatant;

2) RAW264.7 transfected with the tumor-related immune tolerance gene RGS1, under the selection condition of 600 μg/ml G418, a stably transfected cell line was established, and these stably transfected cell surface stimulatory molecules were analyzed by flow cytometry after staining Expression of CD40, CD80 and CD86 and other co-stimulatory molecules; meanwhile, these stably transfected cells were analyzed at different Toll-like receptor linkages (1μg/ml LPS, 25μg/ml PolyI:C 50μg/ml PGN and 100nM 48 hours after the stimulation of B.DNA) the expression of CD40, CD80, CD86 and other co-stimulatory molecules on the cell surface;

3) The total RNA of the RAW264.7 cell line stably transfected with RGS1 was extracted with Trizol reagent, and the total RNA was used for gene chip analysis to analyze the effect of RGS1 on the expression of cytokines, chemokines and intracellular signaling systems;

4) The effect of silencing RGS1 gene on tumor-associated immune tolerance dendritic cells guiding T regulatory cells CD4+CD25+ cells, using the siRNA dendritic cell transfection kit provided by AMAXA company for transfection, targeting the immune tolerance gene RGS1 After siRNA-transfected ovarian tumor-associated immune tolerance dendritic cells were co-cultured with mouse spleen Native T cells for 10 days, the proportion of CD4+CD25+T regulatory cells was analyzed by flow cytometry;

RGS1 target sequence 1#: AATGTTTCTTTTCTGCTAGCCC;

siRNA sequence: sense strand siRNA: UGUUCUUUUCUGCUAGCCCtt and antisense strand siRNA: GGGCUAGCAGAAAAGAACAtt;

RGS1 target sequence 2#: AAAGGATTCGAAAGAACACAG;

siRNA sequence: sense strand siRNA: AGGAUUCGAAAGAACACAGtt antisensestrand siRNA: CUGUGUUCUUUCGAAUCCUtt.

Control siRNA: the artificial mutant form of the above siRNA (ΔsiRNA): siRNA sequence: sensestrand siRNA: UGUUCCCUUCUGCUAGUUCtt and antisense strand siRNA: GAACUAGCAGAAGGGAACAtt; dendritic cells were transfected with AMAXAsiRNA transfection instrument produced in Germany, and the impact on dendritic cells was evaluated;

5) The effect of silencing RGS1 gene on the antigen presentation function of dendritic cells

Ovarian tumor-associated immune tolerance dendritic cells transfected with siRNA targeting immune tolerance gene RGS1, loaded with papillomavirus plasmids, stimulated papillomavirus particle-specific T cell responses, and detected supernatant IFN by ELISA kit - concentration of gamma (interferon gamma);

6) Effect of silencing RGS1 gene on dendritic cells' resistance to tumors on dendritic cells

Double-Promoter pFIV-H ₁ /U ₆ siRNA was used to clone and express the plasmid, and a lentiviral infection system targeting the RGS1 gene was established. The design and insertion of the siRNA template were carried out in full accordance with the methods and steps provided by SBI System Biosciences;

RGS1 siRNA template 1#: 5'ctgagatcgatgatcccacatctggaatct-3 and 3'gactctagctactagggtgtagaccttaga-5;

RGS1 siRNA template 2#: 5'.catactcgagaatcgacagccaag-3' and 3'gtatgagctcttagctgtcggttc-5'; control siRNA template: mutant form of the above siRNA template (ΔsiRNA): 5gtcggatcgatgatcccacatctggaatct-3 and 3'cagcctagctactagggtgtagaccttaga-5;

Dendritic cells were transfected with lentivirus carrying siRNA targeting RGS1 gene, and a lentivirus control targeting RGS1 gene siRNA was set up to transfect dendritic cells with lentivirus, and different transfected dendritic cells and ovarian cancer cells were obtained at 37°C After co-cultured in 10% FCSRPMI1640 medium for one week, observe the morphology, structure and analysis of antigen-stimulating molecules and antigen-presenting function of dendritic cells.

2. The screening and identification method according to claim 1, characterized in that step (1) the ratio of ovarian tumor cells to dendritic cells is 1:10; the ratio of ovarian cancer cell supernatant to fresh medium is 1: 3. (Volume ratio)

3. The method according to claim 1, characterized in that said immune tolerance-related dendritic cells are used to screen the gene RGS1 of immune tolerance-related diseases for the treatment of immune-related diseases, including anti-transplant rejection, Tumors, inflammation, autoimmune diseases.